MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-023-02080-y

Медицинская библиотека · Leukemia · 2023

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.

Rosti Gianantonio, Brümmendorf Tim H, Gjertsen Björn T, Giraldo-Castellano Pilar, Castagnetti Fausto, Gambacorti-Passerini Carlo, Ernst Thomas, Zhao Huadong, Kuttschreuter Luke, Purcell Simon, Giles Francis J, Hochhaus Andreas

Клиническое исследование IV фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and safety after ≥3 years of follow-up in 156 patients with Philadelphia chromosome-positive chronic phase CML by age and Charlson Comorbidity Index scores (without the age component; mCCI) is reported. Cumulative major molecular response rates at any time on treatment were 73.6%, 64.5%, and 74.1% in patients <65, 65-74, and ≥75 years of age, and 77.9%, 63.0%, and 59.3% in patients with mCCI scores 2, 3, and ≥4, respectively. Patients <65, 65-74, and ≥75 years of age experienced grade 3/4 treatment-emergent adverse events (TEAEs) at rates of 74.7%, 78.8%, and 96.4% and permanent discontinuations due to AEs at rates of 22.1%, 39.4%, and 46.4%, respectively. In patients with mCCI 2, 3, and ≥4, respective rates of grade 3/4 TEAEs were 77.8%, 77.8%, and 86.7%, and permanent discontinuations due to AEs were 25.3%, 33.3%, and 43.3%. In conclusion, a substantial proportion of patients maintained/achieved cytogenetic and molecular responses across age groups and mCCI scores. Older patients (≥75 years) and those with high comorbidity burden (mCCI ≥4) may require more careful monitoring due to the increased risk of TEAEs. Clinicaltrials.gov: NCT02228382.

Для цитирования: Rosti Gianantonio, Brümmendorf Tim H, Gjertsen Björn T, Giraldo-Castellano Pilar, Castagnetti Fausto, Gambacorti-Passerini Carlo, Ernst Thomas, Zhao Huadong, Kuttschreuter Luke, Purcell Simon, Giles Francis J, Hochhaus Andreas. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.. Leukemia. 2023. DOI: 10.1038/s41375-023-02080-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.